Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 P996 | DOI: 10.1530/endoabs.110.P996

ECEESPE2025 Poster Presentations Reproductive and Developmental Endocrinology (93 abstracts)

Central precocious puberty in males, whether GnRH analog-treated or untreated, is not associated with fertility or general health problems in mid-adulthood

Liat de Vries 1,2 , Michal Yackobovitch-Gavan 1,2 , Tal Oron 1,2 , Moshe Phillip 1,2 , Joseph Meyerovitch 1,2 , Ariel Tenenbaum 1,2 & Liora Lazar 1,2


1Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 2Schneider Children’s Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, Petach Tikva, Israel


JOINT1611

Context: Knowledge is limited about the long-term health implications of idiopathic central precocious puberty (ICPP) in males, treated or untreated.

Objective: To assess the general health status and metabolic outcomes of men who had ICPP in childhood.

Design: A case control study of an historical cohort from a tertiary pediatric care center.

Patient: The study group comprised 118 men with ICPP aged 29-48 years, of whom 68 had been treated with GnRH-analog (GnRHa) and 50 were untreated. The control group comprised 351 men who were matched for age, year of birth and community clinic: 204 for the GnRHa-treated and 147 for the untreated group.

Methods: We extracted from the computerized database of a health management organization, demographic data, medical history, medications dispensed, recorded anthropometric measurements and laboratory data.

Outcome Measures: The prevalences of fertility issues, cardio-metabolic disorders (obesity, hypertension, dyslipidemia, diabetes), osteoporosis, malignancy and emotional problems.

Results: The median (interquartile range) current ages of the GnRHa-treated and untreated ICPP groups were 40 (29,44) and 44 (40,46) years, respectively. The prevalence of fertility issues was not statistically different between the study and control groups (11.8 vs. 16.2%, P = 0.3), nor between those with ICPP who were treated and untreated (11.8 vs. 18.4%, P = 0.3). For the study and control groups, the rates of obesity, metabolic disorders and cardiovascular diseases were similar. For the study group, both treated and not treated, the rates of osteoporosis and malignancy were less than 10%, and comparable to those of the control group. Emotional problems presented similarly, in less than 20%, of the study and control groups.

Conclusion: ICPP in males, treated or untreated, was not associated with increased fertility problems, cardio-metabolic disorders, malignancy or psychopathology in mid-adulthood. The health status of men who had ICPP was comparable to that of the general population.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches